Hemastatx GmbH
Hemastatx aims to transform field of bleeding disorders. A 2025 BaseLaunch company, Hemastatx'sLead program HMX-001 focuses on advancing afirst-in-class ADAMTS13 antibody addressing severe bleeding in patients with von Willebrand Factor (VWF) disorders, both congential and acquired. HMX-001 is based on an elaborate ex vivo and in vivo PoC package and a robust IP portfolio. We seek financing to advance our program into IND/CTA-enabling studies.
Date, time and room information
Monday, May 4, 15:15 - 15:30, room Singapore
Category
Emerging biotech company
Title of the presentation
Hemastatx: developing a first-in-class therapy for bleeding in patients with VWF disorders
Speaker information
| Name | Position | Institution |
|---|---|---|
| Kevin Hollevoet | CEO & Cofounder |
